Anosmia Market Expected To Grow At 9.5% CAGR Through 2030: What Businesses Need To Know
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anosmia Market CAGR Outlook And Future Development
The anosmia market has experienced robust expansion over the past few years. Projections indicate it will expand from $3.86 billion in 2025 to reach $4.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. The factors contributing to its historical growth include a rise in the occurrence of viral-induced anosmia, heightened recognition of olfactory disorders, improved accessibility to diagnostic instruments, the broadening of ENT specialty care, and an uptick in the reporting of sensory loss cases.
The anosmia market is projected to experience robust expansion in the coming years, with its size forecast to reach $6.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.5%. This growth in the forecast period is primarily driven by intensified research into olfactory nerve regeneration, the wider adoption of novel therapies, the expansion of post-infectious care programs, an increasing demand for quality-of-life treatments, and growing clinical trial activity. Additionally, significant trends during this period include a heightened focus on regenerative therapies, rising utilization of smell training programs, broader adoption of targeted pharmacological treatments, the expansion of diagnostic imaging and testing, and an enhanced emphasis on post-viral recovery management.
Get A Free Sample Report With In-Depth Market Insights:
Anosmia Market Demand Drivers: What’s Powering Industry Growth?
The increasing occurrence of neurological conditions is projected to drive the expansion of the anosmia market. These conditions broadly affect the nervous system, including the brain, spinal cord, and nerves throughout the body. The growing prevalence of neurological disorders is attributed to an aging population and a rise in chronic diseases such as diabetes and hypertension. Such disorders can induce anosmia by damaging the olfactory pathways or brain regions responsible for processing smell, leading to an inability to detect or perceive odors. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating this could reach 13.8 million by 2060. Thus, the increasing incidence of neurological disorders is propelling the growth of the anosmia market.
Anosmia Market Segment Analysis And Revenue Potential
The anosmia market covered in this report is segmented –
1) By Type: Idiopathic Anosmia, Congenital Anosmia
2) By Treatment: Therapies, Medications
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Idiopathic Anosmia: Partial Idiopathic Anosmia, Complete Idiopathic Anosmia
2) By Congenital Anosmia: Isolated Congenital Anosmia, Syndromic Congenital Anosmia (Associated With Other Conditions Or Syndromes)
Anosmia Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating in the anosmia market are focusing on developing advanced delivery systems, such as soft-mist nasal sprays, to enhance efficacy, improve drug absorption, and precisely target the olfactory region. Soft-mist nasal spray technology uses controlled droplet size and low spray velocity to maximize deposition in the olfactory region, thereby increasing its therapeutic effect. For instance, in April 2025, Cyrano Therapeutics, a U.S.-based clinical-stage regenerative medicine company, completed enrollment in the Phase 2 FLAVOR trial of its soft-mist nasal spray candidate, CYR-064, for post-viral smell loss. The product features a patent-protected intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor designed to boost olfactory neuron excitability, and, by using the Ursatec 3K pump system combined with Resyca’s soft-mist spray technology, it achieves precise and targeted deposition into the olfactory region.
Anosmia Market Key Players Shaping Industry Direction
Major companies operating in the anosmia market are Cyrano Therapeutics, Regeneron Pharmaceuticals, Novartis AG, GlaxoSmithKline PLC, Otsuka Pharmaceutical Co Ltd, Bayer AG, AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc, Sanofi SA, NeuroNascent Inc, Immunome Therapeutics, Olfactory Therapeutics Ltd, ENT Therapeutics Inc, NeuroSense Therapeutics LLC, SmellSense Bio, Olfactricity Therapeutics, Sensory Neurogenics Inc, Olfaxion Biotech, SmellGen Therapeutics, Post-Viral Sensory Recovery Inc, Hyposmia Therapeutics LLC
View The Full Anosmia Market Report:
Anosmia Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the anosmia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the market going forward. The regions covered in the anosmia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
